Evelo Biosciences to Present Preclinical Data from its EDP1503 Oncology Program at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting
Details of the accepted abstract are as follows:
Title: Monoclonal microbial EDP1503 induces anti-tumor responses via gut-mediated activation of both innate and adaptive immunity
Poster Session Date & Time:
Poster Session: Regular and Young Investigator Award Posters
Abstract: P691
Authors:
The accepted abstract is listed below and available online on the
About
Evelo currently has three product candidates, EDP1066 and EDP1815 for the treatment of inflammatory diseases and EDP1503 for the treatment of cancer. Evelo is also advancing additional oral biologics through preclinical development in other disease areas.
For more information, please visit www.evelobio.com.
Contact
jcotrone@evelobio.com
Source: Evelo Biosciences, Inc.